The mission of the Journal of Thrombosis and Haemostasis is to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community. The Journal publishes high quality, original research reports, state of the art reviews, brief reports, case reports, invited commentaries on publications in the Journal, forum articles, correspondence and announcements. Editors invite both fundamental and clinical contributions. These include basic manuscripts on blood coagulation and fibrinolysis, proteins and reactions, blood platelets, and the interaction of all these components with other biological systems such as, but not limited to, the vessel wall, blood cells, and invading organisms. Clinical manuscripts can cover a wide variety of topics including venous thrombosis and arterial diseases, plus hemophilia and other bleeding disorders, as well as platelet diseases. The subject area of clinical manuscripts can range from etiology to diagnostics, prognosis, prevention, and treatment.

Aims and scope. The mission of the Journal of Thrombosis and Haemostasis is to advance science related to the important medical problems of thrombosis, bleeding disorders and vascular biology through the diffusion and exchange of information and ideas within the international research community. The Journal publishes high quality, original research reports, state of the art reviews, brief reports, case reports, invited commentaries on publications in the Journal, forum articles, correspondence and announcements. Editors invite both fundamental and clinical contributions. These include basic manuscripts on blood coagulation and fibrinolysis, proteins and reactions, blood platelets, and the interaction of all these components with other biological systems such as, but not limited to, the vessel wall, blood cells, and invading organisms. Clinical manuscripts can cover a wide variety of topics including venous thrombosis and arterial diseases, plus hemophilia and other bleeding disorders, as well as platelet diseases. The subject area of clinical manuscripts can range from etiology to diagnostics, prognosis, prevention, and treatment.

Subscription information. The Journal of Thrombosis and Haemostasis is published in 12 issues per year. Institutional subscription prices for 2016 are:

Print & Online: €1500 (Europe), $1160 (UK), $1515 (The Americas), US$319 (Rest of World). Prices are exclusive of tax. Asian-Pacific GST, Canadian GST and European VAT will be applied at the appropriate rates. For more information on current tax rates, please go to wileyonlinelibrary.com/tax-vat. The price includes online access to the current and all online back files to January 1st 2012, where available. For other pricing options, including access information and terms and conditions, please visit wileyonlinelibrary.com/access.

Delivery Terms and Legal Title. Where the subscription price includes print issues and delivery is to the recipient’s address, delivery terms are Delivered at Place (DAP); the recipient is responsible for paying any import duty or taxes. Title to all issues transfers FOB our shipping point, freight prepaid. We will endeavour to fulfil claims for missing or damaged copies within six months of publication, within our reasonable discretion and subject to availability.

Copyright and copying. Copyright © 2016 International Society on Thrombosis and Haemostasis. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to photocopy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution for advertising or promotional purposes, for creating new collective works or for resale. Specific requests should be addressed to permissions@wiley.com

Contact details. Journal of Thrombosis and Haemostasis is published by Wiley Periodicals, Inc., Commerce Place, 350 Main Street, Malden, MA 02148-0108, USA. Production Editor: Liz Zargaras (email: jth@wiley.com). Advertising: Stephen Donohue (email: sdonohue@wiley.com). Reprints: Daniel Geary (email: dgeary@wiley.com). Journal Customer Services: For ordering information, claims and any enquiry concerning your journal subscription please go to wileyonlinelibrary.com/support or contact your nearest office: Americas: Email: cs-journals@wiley.com; Tel: +1 781 888 8598 or 1 800 835 6770 (Toll free in the USA & Canada). Europe, Middle East and Africa: Email: cs-journals@wiley.com; Tel: +44 (0) 1865 787385. Asia Pacific: Email: cs-journals@wiley.com; Tel: +65 6511 8100. Japan: For Japanese speaking support, Email: cs-japan@wiley.com; Tel: +65 6511 8101 or Tel (toll-free): 005 316 50 49. Visit our Online Customer Help available in 7 languages at www.wileycustomerservice.com Ask Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, engaging in community philanthropy, reducing our carbon footprint, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts. Follow our progress at www.wiley.com/go/citizenship.

Disclaimer. The Publisher, the International Society on Thrombosis and Haemostasis and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, the International Society on Thrombosis and Haemostasis and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, the International Society on Thrombosis and Haemostasis and Editors of the products advertised. The JOURNAL OF THROMBOSIS AND HAEMOSTASIS (ISSN 1538-7933) is published monthly on behalf of the International Society of Thrombosis and Haemostasis by Wiley Subscription Services, Inc., a Wiley Company, 111 River St., Hoboken, NJ 07030-5774, USA. Postmaster: Send all address changes to JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Journal Customer Services, John Wiley & Sons Inc., C/O The Sheridan Press, PO Box 465, Hanover, PA 17331.

For submission instructions, subscription and all other information visit: http://wileyonlinelibrary.com/journal/jth

Contact: View this journal online at wileyonlinelibrary.com/journal/jth

ISSN 1538-7933 (Print)
ISSN 1538-7836 (Online)


Printed in the USA by The Sheridan Group.
Editorial
1493 No P Please F. R. Rosendaal and P. H. Reitsma
1494 What the neighbors say
Forum
1495 Unique challenges and experiences of trainees from Reach-the-World countries J. Etulain
Review Articles
1498 Factor XII: form determines function S. De Maat and C. Maas
CLINICAL HAEMOSTASIS AND THROMBOSIS
Case of the Month
1517 Neutralizing autoantibody against factor XIII A subunit resulted in severe bleeding diathesis with a fatal outcome – characterization of the antibody K. Pénzes, K. Rázsó, É. Katona, A. Kerényi, M. Kun and L. Muszbek
Original Articles
1521 Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial M. Carcao, M. Zak, F. Abdul Karim, H. Hanabusa, S. Kearney, M.-Y. Lu, P. Persson, S. Rangarajan and E. Santagostino
1530 IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis H. Kelchtermans, L. Pelkmans, B. de Laat and K. M. Devreese
1549 Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect M. E. de la Morena-Barrio, I. Martínez-Martínez, C. de Cos, E. Wypasek, V. Roldán, A. Undas, M. van Scherpenzeel, D. J. Lefeber, M. Toderici, T. Sevivas, F. España, J. Jaeken, J. Corral and V. Vicente
Brief Report
1572 Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors D. D. Ribeiro, W. M. Lijfering, F. R. Rosendaal and S. C. Cannegieter
COAGULATION
Original Articles
1579 Factor VIII chromogenic assays can be used for potency labeling and postadministration monitoring of N8-GP W. Pickering, M. Hansen, M. Kjalke and M. Ezban
FIBRINOLYSIS
Commentary
1600 Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency M. B. Boffa
In Focus
Commentary
1615 Backseat drivers: passenger mutations take control of experimental phenotypes B. J. M. van Vlijmen and R. J. Westrick
In Focus
Original Article
1629 Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity X. Zhou, S. D. Weeks, P. Ameloot, N. Callewaert, S. V. Strelkov and P. J. Declerck
PLATELETS
Commentary
1639 Protease-activated receptor 4 is more important than protease-activated receptor 1 for the thrombin-induced procoagulant effect on platelets T. L. Lindahl, A. S. Macwan and S. Ramström
In Focus


VASCULAR BIOLOGY

Original Article


Recommendations and Guidelines

1668 Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH A. Iorio, A. M. Barbara, F. Bernardi, D. Lillicrap, M. Makris, F. Peyvandi and F. Rosendaal for the Subcommittee on Factor VIII, Factor IX & Rare Coagulation Disorder


1677 Erratum

1678 Announcements

Cover image: A hypothetical model for thrombus reinforcement by factor XII-dependent coagulation pp 1498–1506.